IP Library Granted Patent US 11,293,017
Granted Patent B2
US 11,293,017 · App. 16/304,389 · Granted Apr 5, 2022

Oligonucleotide probes and uses thereof

Inventors: Valeriy Domenyuk (Phoenix, AZ); Tassilo Hornung (Phoenix, AZ); Mark Miglarese (Phoenix, AZ); David Spetzler (Paradise Valley, AZ)
Assignee: Caris Science, Inc.
C12N15/1006C12N15/115C40B20/02C40B20/04C40B40/08C12N2310/16C12N2320/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,293,017
App. No.
16/304,389
Granted
Apr 5, 2022
Kind
B2
Abstract

Methods and compositions are provided to identify oligonucleotides that bind targets of interest. The targets include tissues, cells, circulating biomarkers such as microvesicles, including those derived from various diseases. The oligonucleotides can be used in diagnostic and therapeutic applications.

Claims (25)

1. A method of enriching an oligonucleotide probe library comprising a plurality of oligonucleotides, the method comprising:

(a) providing a planar support arrayed with a plurality of samples, wherein a portion of the plurality of samples are cancer samples and another portion of the plurality of samples are non-cancer control samples, and wherein each of the plurality of samples comprises microvesicles;

(b) contacting the plurality of samples arrayed on the planar support with the plurality of oligonucleotides; and

(c) recovering members of the oligonucleotide probe library that bound to members of the plurality of samples, thereby enriching the oligonucleotide probe library.

2. The method of claim 1 , further comprising repeating steps (a)-(c) at least 5 times.

3. The method of claim 1 , wherein the unenriched oligonucleotide probe library comprises at least 10 6 different oligonucleotide sequences.

4. The method of claim 1 , wherein the plurality of cancer samples comprises a bodily fluid or a fraction or derivative thereof.

5. The method of claim 4 , wherein the bodily fluid comprises at least one of peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, Cowper's fluid, pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair oil, tears, cyst fluid, pleural fluid, peritoneal fluid, malignant fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, and other lavage fluids.

6. The method of claim 4 , wherein the bodily fluid comprises blood or a derivative thereof.

7. The method of claim 1 , further comprising isolating the microvesicles prior to step (a).

8. The method of claim 7 , wherein isolating the microvesicles comprises at least one of filtration, ultracentrifugation, affinity isolation, size exclusion chromatography and polymer precipitation.

9. The method of claim 8 , wherein the polymer comprises polyethylene glycol (PEG).

10. The method of claim 1 , wherein the planar support comprises a well, a glass slide or a membrane.

11. The method of claim 10 , wherein the membrane comprises a polymer membrane or a nitrocellulose membrane.

12. The method of claim 1 , wherein the plurality of cancer samples differs from the plurality of control samples according to a phenotype of interest, some or all members of the plurality of cancer samples and plurality of control samples are from different sections of a same substrate, and some or all members of the plurality of cancer samples and plurality of control samples are scraped or microdissected from the same substrate.

13. A method of characterizing a cancer in a sample comprising:

(a) enriching a plurality of oligonucleotides to characterize the cancer according to the method of claim 1 ;

(b) arraying at least one sample on a substrate;

(c) contacting the substrate with the plurality of oligonucleotides enriched in step (a); and

(d) measuring a presence or level of a complex formed between members of the plurality of oligonucleotides and the samples arrayed on the substrate, wherein the presence or level is used to characterize the cancer.

14. The method of claim 13 , wherein the sample comprises microvesicles isolated from a bodily fluid.

15. The method of claim 14 , wherein the bodily fluid comprises peripheral blood, sera, plasma, ascites, urine, cerebrospinal fluid (CSF), sputum, saliva, bone marrow, synovial fluid, aqueous humor, amniotic fluid, cerumen, breast milk, broncheoalveolar lavage fluid, semen, prostatic fluid, cowper's fluid or pre-ejaculatory fluid, female ejaculate, sweat, fecal matter, hair oil, tears, cyst fluid, pleural and peritoneal fluid, pericardial fluid, lymph, chyme, chyle, bile, interstitial fluid, menses, pus, sebum, vomit, vaginal secretions, mucosal secretion, stool water, pancreatic juice, lavage fluids from sinus cavities, bronchopulmonary aspirates, blastocyl cavity fluid, or umbilical cord blood.

16. The method of claim 13 , wherein the measuring comprises sequencing, amplification, hybridization, gel electrophoresis, chromatography, or visualization.

17. The method of claim 16 , wherein the hybridization comprises contacting the sample with at least one labeled probe that is configured to hybridize with members of the plurality of oligonucleotides.

18. The method of claim 16 , wherein the visualization comprises visualizing a signal linked directly or indirectly to members of the plurality of oligonucleotides.

Assignments (6)
RELEASE OF SECURITY INTEREST IN PATENTS AT REEL/FRAME NO. 62419/0390 Recorded Apr 1, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
To: CARIS MPI, INC.; CARIS SCIENCE, INC.
Reel/Frame 075424/0290 →
PATENT SECURITY AGREEMENT Recorded Apr 1, 2026
From: CARIS SCIENCE, INC.
To: BLUE OWL CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
Reel/Frame 075362/0668 →
RELEASE OF SECURITY INTEREST Recorded Jan 18, 2023
From: SIXTH STREET SPECIALTY LENDING, INC. (F/K/A TPG SPECIALTY LENDING, INC.)
To: CARIS SCIENCE, INC.; CARIS MPI, INC.
Reel/Frame 062419/0322 →
SECURITY INTEREST Recorded Jan 18, 2023
From: CARIS MPI, INC.; CARIS SCIENCE, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 062419/0390 →
SECURITY INTEREST Recorded Apr 3, 2020
From: CARIS MPI, INC.; CARIS SCIENCE, INC.
To: TPG SPECIALTY LENDING, INC.
Reel/Frame 052313/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 26, 2020
From: DOMENYUK, VALERIY; HORNUNG, TASSILO; MIGLARESE, MARK; SPETZLER, DAVID
To: CARIS SCIENCE, INC.
Reel/Frame 052237/0282 →
Continuity (9)
Provisional Application 62341617 · May 25, 2016
Provisional Application 62413361 · Oct 26, 2016
Provisional Application 62420497 · Nov 10, 2016
Provisional Application 62432561 · Dec 9, 2016
Provisional Application 62441527 · Jan 2, 2017
Provisional Application 62457691 · Feb 10, 2017
Provisional Application 62472953 · Mar 17, 2017
Provisional Application 62508353 · May 18, 2017
Related Publication 20190367903A1 · Dec 5, 2019